Lv3
272 积分 2025-11-28 加入
A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
19天前
已关闭
P.577 ADVANCE: phase 2, randomised, double-blind, placebo-controlled study of adjunctive pimavanserin in patients with negative symptoms of schizophrenia
1个月前
已关闭
Ultrasound‑based techniques in diabetic bone disease: state of the art and future perspectives
1个月前
已完结
Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study
1个月前
已完结
Quantitative electroencephalography parameters as neurophysiological biomarkers of schizophrenia-related deficits: A Phase II substudy of patients treated with iclepertin (BI 425809)
1个月前
已完结
A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia
1个月前
已关闭
Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058
1个月前
已完结
Long-term efficacy, safety, and tolerability of xanomeline and trospium chloride in schizophrenia: A 52-week, open-label trial (EMERGENT-5)
1个月前
已完结
SAFETY AND EFFICACY OF KARXT IN PATIENTS WITH SCHIZOPHRENIA IN THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EMERGENT TRIALS
1个月前
已完结
皖公网安备34019202002308
